Search bioRxiv⌕ Search

Biology subjects

Califano, A.

Publications and source records attributed to Califano, A..

At least 19 recordsLinked to original sources

DoFormer: Causal Transformer for Gene Perturbation

Learning causal gene regulatory mechanisms from single-cell data, and thereby predicting the effects of unseen perturbations, remains challenging. Observational RNA-seq data alone is insufficient for causal modeling, whereas perturbational data is essential. Classical causal inference methods often rely on unrealistic directed acyclic graph (DAG) assumptions and are not well suited to integrating multimodal data. Current transcriptomic foundation models also typically treat observational and perturbational data identically, limiting their ability to model perturbations. We present DoFormer, a causal multimodal Transformer that makes no DAG assumptions and leverages rich perturbational data to accurately predict previously unseen perturbations. DoFormer enables principled in silico perturbations by adapting the causal do-operator within the attention mechanism: the perturbed gene is set to the intervention value and prevented from attending to other genes, allowing the model to fully distinguish observational from interventional regimes. We train DoFormer using biologically informed loss functions and evaluate it with comprehensive perturbation prediction metrics. DoFormer substantially improves perturbation prediction relative to baseline and prior foundation models, underscoring the importance of intervention-aware architectures and biologically grounded objectives for causal modeling in single-cell genomics.

bioinformatics↗

TMPO promotes cellular dissemination and metastasis in circulating tumor cells

Metastasis--the process by which cancer cells spread beyond the primary tumor to distant organs--accounts for the vast majority of cancer-related deaths. To elucidate mechanisms underlying dissemination and metastasis in prostate cancer, we have investigated circulating tumor cells (CTCs) obtained from genetically engineered mouse models (GEMMs). The phenotypic and molecular properties of the CTCs, and organoids derived from these CTCs, closely model the tumor and metastatic phenotypes of their parental GEMMs. Moreover, organoids derived from individual CTCs exhibit molecular and morphological heterogeneity that is associated with distinct metabolic states as well as differences in human prostate cancer outcome. Using computational systems analyses, we have identified TMPO, encoding the nuclear membrane protein lamina-associated polypeptide 2 (Lap2), as a key driver of this heterogeneity. TMPO activity is upregulated in advanced human prostate tumors, metastases, and CTCs, and is associated with adverse clinical outcome. Our findings indicate that TMPO promotes dissemination and metastasis in vivo by enhancing survival in conditions of metabolic stress, and reveal a novel mechanistic link between CTC heterogeneity, stress adaptation, and metastatic potential.

cell biology↗

Systematic elucidation and pharmacologic targeting on non-oncogene dependencies in imatinib-resistant gastrointestinal stromal tumor

Treatment of gastrointestinal stromal tumor (GIST) with imatinib and other KIT-targeting drugs has improved outcomes significantly. However, most patients with advanced GIST eventually develop imatinib resistance and succumb to disease. We have developed mutation-agnostic, network-based methodologies to systematically elucidate and pharmacologically target Master Regulator (MR) proteins--critical non-oncogene dependencies--in cancer cells. Unsupervised, MR-based clustering of 34 GIST patient tumor samples produced two clusters, one of which contained all imatinib-resistant tumors. Analysis of 9 single-cell RNA profiles of high-risk GIST revealed that tumors with clinical progression on imatinib harbored large subpopulations enriched for the MR-activity signature of imatinib-resistant tumors, while tumors with resistance-associated mutations but without overt progression showed smaller, variably sized enriched subpopulations. High-throughput profiling of transcriptional responses by two GIST cell lines to FDA-approved and late-stage experimental drugs identified six candidate drugs that reversed the MR activity of imatinib-resistant GIST. Predictions were validated in two imatinib-resistant, patient-derived xenograft (PDX) models. The top prediction, linifanib, induced marked tumor growth inhibition in both PDXs across a wide dose range; selinexor and selumetinib were also effective compared to imatinib. We confirmed in vivo MR-activity reversal by these drugs, but not by ineffective drugs.

cancer biology↗

Complex Assembly and Activity States as Multifaceted Protein Attributes Explaining Phenotypic Variability

Cell function studies primarily focus on measuring overall molecular abundances while often overlooking critical clues--including protein modifications and molecular interaction networks--that critically determine the functional properties of the cell. In prior work, we introduced a suite of methods to reveal context-specific transcription factor-gene regulatory networks, kinase-substrate networks, and protein interaction networks and leveraged them to gain deeper insights into transcriptional regulation and signal transduction. However, the complex interdependencies between these networks are still elusive. To address this challenge, we introduce a multi-omics framework, aimed at harnessing measured or inferred protein activity in context-specific networks, which yields deeper functional insights into mechanisms underlying molecular phenotypes, compared to protein abundance alone. As proof of concept, we utilized progressively differentiated instances of HeLa CCL2 and Kyoto cell lines to explore the role of protein complexes and interactions in cell doubling time and susceptibility to Salmonella Typhimurium infection. Notably, this analysis underscores the pivotal role of protein interaction networks in linking molecular profiles to phenotypic outcomes, thus providing a highly generalizable framework for multi-omics dataset analysis.

systems biology↗

CD155 regulates tumor growth and immune evasion in diffuse midline glioma.

Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune checkpoint inhibitors have failed to prolong survival for DMG patients. In this study, we analyzed the expression of immune checkpoint molecules in human and murine DMG cells, as well as primary brain tumor samples, and identified CD155 as the most highly expressed. When murine DMG cells were co-cultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 led to induction of apoptosis of DMG cells and to delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified FOXM1 as a key target of CD155. Notably, FOXM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thiostrepton, a FOXM1-targeting agent, delayed tumor growth and prolonged survival. These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease. Conflict-of-interest statementThe authors have declared that no conflict of interest exists.

cancer biology↗

GREmLN: A Cellular Regulatory Network-Aware Transcriptomics Foundation Model

AO_SCPLOWBSTRACTC_SCPLOWThe ever-increasing availability of large-scale single-cell profiles presents an opportunity to develop foundation models to capture cell properties and behavior. However, standard language models such as transformers benefits from sequentially structured data with well defined absolute or relative positional relationships, while single cell RNA data have orderless gene features. Molecular-interaction graphs, such as gene regulatory networks (GRN) or protein-protein interaction (PPI) networks, offer graph structure-based models that effectively encode both non-local gene token dependencies, as well as potential causal relationships. We introduce GREmLN (Gene Regulatory Embedding-based Large Neural model), a foundation model that leverages graph signal processing to embed gene token graph structure directly within its attention mechanism, producing biologically informed single cell specific gene embeddings. Our model faithfully captures transcriptomics landscapes and achieves superior performance relative to state-of-the-art baselines on cell type annotation, graph structure understanding, and fine-tuned reverse perturbation prediction tasks. It offers a unified and interpretable framework for learning high-capacity foundational representations that capture complex, long-range regulatory dependencies from high-dimensional single-cell transcriptomic data. Moreover, the incorporation of graph-structured inductive biases enables more parameter-efficient architectures and accelerates training convergence.

bioinformatics↗

Single Nuclei-Derived Molecular Subtypes of Gastrointestinal Stromal Tumors Correlate with Clinicopathologic Features and Predict Clinical Outcomes

Historically, gastrointestinal stromal tumor (GIST) has been subtyped by oncogenic driver mutations. However, tumors with the same mutational profile can have variable biology. To further explore the impact of molecular diversity on GIST biology, we performed single nucleus RNA sequencing on 16 primary GIST and utilized an integrated single cell atlas of the normal GI tract composed from multiple publicly available datasets to identify six distinct GIST cell states. We then statistically estimated the relative abundances of these profiles in bulk transcriptomic data. These were used to define six common GIST molecular subtypes based upon one or two predominant tumor cell states. We found that these molecular subtypes correlate with tumor locations, mutational profiles, and patient outcomes, and validated these subtypes in an independent international cohort. These molecular subtypes have the potential to be used for clinical prognostication for patients with GIST, identifying new therapeutic targets, and studying the cell of transformation of GIST.

cancer biology↗

Identification and Targeting of Regulators of SARS-CoV-2-Host Interactions in the Airway Epithelium.

Although the impact of SARS-CoV-2 in the lung has been extensively studied, the molecular regulators and targets of the host-cell programs hijacked by the virus in distinct human airway epithelial cell populations remain poorly understood. This is in part ascribed to the use of nonprimary cell systems, overreliance on single-cell gene expression profiling that does not ultimately reflect protein activity, and bias toward the downstream effects rather than their mechanistic determinants. Here we address these issues by network-based analysis of single cell transcriptomic profiles of pathophysiologically relevant human adult basal, ciliated and secretory cells to identify master regulator (MR) protein modules controlling their SARS-CoV-2-mediated reprogramming. This uncovered chromatin remodeling, endosomal sorting, ubiquitin pathways, as well as proviral factors identified by CRISPR analyses as components of the host response collectively or selectively activated in these cells. Large-scale perturbation assays, using a clinically relevant drug library, identified 11 drugs able to invert the entire MR signature activated by SARS-CoV-2 in these cell types. Leveraging MR analysis and perturbational profiles of human primary cells represents a novel mechanism-based approach and resource that can be directly generalized to interrogate signatures of other airway conditions for drug prioritization.

cell biology↗

pyVIPER: A fast and scalable Python package for rank-based enrichment analysis of single-cell RNASeq data

SummarySingle-cell sequencing has revolutionized biomedical research by offering insights into cellular heterogeneity at unprecedented resolution. Yet, the low signal-to-noise ratio, characteristic of single-cell RNA sequencing (scRNASeq), challenges quantitative analyses. We have shown that gene regulatory network (GRN) analysis can help overcome this obstacle and support mechanistic elucidation of cellular state determinants, for example by using the VIPER algorithm to identify Master Regulator (MR) proteins from gene expression data. A key challenge, as the size and complexity of scRNASeq datasets grow, is the need for highly scalable tools supporting the analysis of large-scale datasets with up to hundreds of thousands of cells. To address it, we introduce pyVIPER, a fast, memory-efficient, and highly scalable Python toolkit for assessing protein activity in large-scale scRNASeq datasets. pyVIPER supports multiple enrichment analysis algorithms, data transformation/postprocessing modules, a novel data structure for GRNs manipulation, and seamless integration with AnnData, Scanpy and several widely adopted machine learning libraries. Compared to VIPER, benchmarking reveals orders of magnitude runtime reduction for large datasets--i.e., from hours to minutes-- thus supporting VIPER-based analysis of virtually any large-scale single-cell dataset, as well as integration with other Python-based tools. Availability and ImplementationpyVIPER is available on GitHub (https://github.com/alevax/pyviper) and PyPI (https://pypi.org/project/viper-in-python/). Contactav2729@cumc.columbia.edu Supplementary informationSupplementary data are available at Bioinformatics online. Accompanying data for the tutorials are available on Zenodo (https://zenodo.org/records/10059791).

bioinformatics↗

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer

Although localized prostate cancer is relatively indolent, advanced prostate cancer manifests with aggressive and often lethal variants, including neuroendocrine prostate cancer (NEPC). To identify drivers of aggressive prostate cancer, we leveraged Sleeping Beauty (SB) transposon mutagenesis in a mouse model based on prostate-specific loss-of-function of Pten and Tp53. Compared with control mice, SB mice developed more aggressive prostate tumors, with increased incidence of metastasis. Notably, a significant percentage of the SB prostate tumors display NEPC phenotypes, and the transcriptomic features of these SB mouse tumors recapitulated those of human NEPC. We identified common SB transposon insertion sites (CIS) and prioritized associated CIS-genes differentially expressed in NEPC versus non-NEPC SB tumors. Integrated analysis of CIS-genes encoding for proteins representing upstream, post-translational modulators of master regulators controlling the transcriptional state of SB-mouse and human NEPC tumors identified sirtuin 1 (Sirt1) as a candidate mechanistic determinant of NEPC. Gain-of-function studies in human prostate cancer cell lines confirmed that SIRT1 promotes NEPC, while its loss-of-function or pharmacological inhibition abrogates NEPC. This integrative analysis is generalizable and can be used to identify novel cancer drivers for other malignancies. SummaryUsing an unbiased forward mutagenesis screen in an autochthonous mouse model, we have investigated mechanistic determinants of aggressive prostate cancer. SIRT1 emerged as a key regulator of neuroendocrine prostate cancer differentiation and a potential target for therapeutic intervention.

cancer biology↗

Disentangling the splicing factor programs underlying complex molecular phenotypes

Splicing factors control exon inclusion in messenger RNAs, shaping transcriptome and proteome diversity. Their catalytic activity is regulated by multiple layers, making single-omic measurements on their own fall short in identifying which splicing factors underlie a phenotype. Here, we posit that splicing factor activity can be estimated from changes in exon inclusion. To test this hypothesis, we benchmarked methods for constructing splicing factor[->]exon networks and estimating splicing factor activity. We found that combining RNA-seq perturbation-based networks with VIPER (Virtual Inference of Protein Activity by Enriched Regulon analysis) accurately captures splicing factor activation as modulated by multiple regulatory layers. This approach integrates splicing factor regulation into a single score derived solely from exon inclusion signatures, allowing functional interpretation of heterogeneous conditions. As a proof of concept, we identify recurrent cancer splicing programs, revealing oncogenic- and tumor suppressor-like splicing factors missed by conventional methods. These programs correlate with patient survival and key cancer hallmarks: initiation, proliferation, and immune evasion. Altogether, we show splicing factor activity can be accurately estimated from exon inclusion changes, enabling comprehensive analyses of splicing regulation with minimal data requirements.

systems biology↗

Reverse engineering neuron type-specific and type-orthogonal splicing-regulatory networks using single-cell transcriptomes

Cell type-specific alternative splicing (AS) enables differential gene isoform expression between diverse neuron types with distinct identities and functions. Current studies linking individual RNA-binding proteins (RBPs) to AS in a few neuron types underscore the need for holistic modeling. Here, we use network reverse engineering to derive a map of the neuron type-specific AS regulatory landscape from 133 mouse neocortical cell types defined by single-cell transcriptomes. This approach reliably inferred the regulons of 350 RBPs and their cell type-specific activities. Our analysis revealed driving factors delineating neuronal identities, among which we validated Elavl2 as a key RBP for MGE-specific splicing in GABAergic interneurons using an in vitro ESC differentiation system. We also identified a module of exons and candidate regulators specific for long- and short-projection neurons across multiple neuronal classes. This study provides a resource for elucidating splicing regulatory programs that drive neuronal molecular diversity, including those that do not align with gene expression-based classifications.

systems biology↗

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Despite the potential of targeted epigenetic therapies, most cancers do not respond to current epigenetic drugs. The Polycomb repressive complex EZH2 inhibitor tazemetostat was recently approved for the treatment of SMARCB1-deficient epithelioid sarcomas, based on the functional antagonism between PRC2 and loss of SMARCB1. Through the analysis of tazemetostat-treated patient tumors, we recently defined key principles of their response and resistance to EZH2 epigenetic therapy. Here, using transcriptomic inference from SMARCB1-deficient tumor cells, we nominate the DNA damage repair kinase ATR as a target for rational combination EZH2 epigenetic therapy. We show that EZH2 inhibition promotes DNA damage in epithelioid and rhabdoid tumor cells, at least in part via its induction of the transposase-derived PGBD5. We leverage this collateral synthetic lethal dependency to target PGBD5-dependent DNA damage by inhibition of ATR but not CHK1 using elimusertib. Consequently, combined EZH2 and ATR inhibition improves therapeutic responses in diverse patient-derived epithelioid and rhabdoid tumors in vivo. This advances a combination epigenetic therapy based on EZH2-PGBD5 synthetic lethal dependency suitable for immediate translation to clinical trials for patients.

cancer biology↗

The regulatory architecture of the primed pluripotent cell state

Although numerous studies have focused on defining transcriptional cell states in normal and disease contexts, the gene regulatory architecture that governs and defines specific mammalian cell states remains poorly understood. Here we present an integrative computational and experimental systems biology approach to elucidate the regulatory architecture of a conserved cell state of critical importance in development and stem cell biology, namely primed state pluripotency. We have used an unbiased approach to analyze protein activity profiles from mouse epiblast stem cells (EpiSCs), leading to identification and experimental confirmation of 132 transcription factors that are master regulators (MRs) of primed state pluripotency. These MRs include known as well as novel factors, many of which were further validated for their role in lineage-specific differentiation using CRISPR-mediated functional assays. To assemble a comprehensive regulatory network, we silenced each of the 132 MRs to assess their effects on the other MRs and their transcriptional targets, yielding a network of 1,273 MR[->]MR interactions. Network architecture analyses revealed four functionally distinct MR modules (communities), largely independent of lineage-specific differentiation, and identified key Speaker and Mediator MRs based on their hierarchical rank and centrality in mediating information flow in the pluripotent cell. Taken together, our findings elucidate the de-centralized logic of a "communal interaction" model in which the balanced activities of four MR communities maintain pluripotency, and define the primed pluripotent cell state in terms of its transcriptional regulatory network.

systems biology↗

Elucidation and Pharmacologic Targeting of Master Regulator Dependencies in Coexisting Diffuse Midline Glioma Subpopulations

Diffuse Midline Gliomas (DMGs) are universally fatal, primarily pediatric malignancies affecting the midline structures of the central nervous system. Despite decades of clinical trials, treatment remains limited to palliative radiation therapy. A major challenge is the coexistence of molecularly distinct malignant cell states with potentially orthogonal drug sensitivities. To address this challenge, we leveraged established network-based methodologies to elucidate Master Regulator (MR) proteins representing mechanistic, non-oncogene dependencies of seven coexisting subpopulations identified by single-cell analysis--whose enrichment in essential genes was validated by pooled CRISPR/Cas9 screens. Perturbational profiles of 372 clinically relevant drugs helped identify those able to invert the activity of subpopulation-specific MRs for follow-up in vivo validation. While individual drugs predicted to target individual subpopulations--including avapritinib, larotrectinib, and ruxolitinib--produced only modest tumor growth reduction in orthotopic models, systemic co-administration induced significant survival extension, making this approach a valuable contribution to the rational design of combination therapy.

systems biology↗

Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination Therapy

Tumors frequently harbor isogenic yet epigenetically distinct subpopulations of multi-potent cells with high tumor-initiating potential--often called Cancer Stem-Like Cells (CSLCs). These can display preferential resistance to standard-of-care chemotherapy. Single-cell analyses can help elucidate Master Regulator (MR) proteins responsible for governing the transcriptional state of these cells, thus revealing complementary dependencies that may be leveraged via combination therapy. Interrogation of single-cell RNA sequencing profiles from seven metastatic breast cancer patients, using perturbational profiles of clinically relevant drugs, identified drugs predicted to invert the activity of MR proteins governing the transcriptional state of chemoresistant CSLCs, which were then validated by CROP-seq assays. The top drug, the anthelmintic albendazole, depleted this subpopulation in vivo without noticeable cytotoxicity. Moreover, sequential cycles of albendazole and paclitaxel--a commonly used chemotherapeutic --displayed significant synergy in a patient-derived xenograft (PDX) from a TNBC patient, suggesting that network-based approaches can help develop mechanism-based combinatorial therapies targeting complementary subpopulations. Statement of significanceNetwork-based approaches, as shown in a study on metastatic breast cancer, can develop effective combinatorial therapies targeting complementary subpopulations. By analyzing scRNA-seq data and using clinically relevant drugs, researchers identified and depleted chemoresistant Cancer Stem-Like Cells, enhancing the efficacy of standard chemotherapies.

systems biology↗

Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium

Drug Mechanism of Action (MoA) is often represented as a small repertoire of tissue-independent, high-affinity binding targets. Yet drug activity and polypharmacology are also manifested through a broad range of off-target and tissue-specific effector proteins. To address this dichotomy, we generated a compendium of drug perturbation profiles for >700 oncology drugs in cell lines representing high-fidelity models of 23 aggressive tumor subtypes, as well as an integrative framework for the proteome-wide assessment of drug-mediated, tissue-specific differential protein activity. Extending MoA and polypharmacology assessment via proteome-wide, multi-tissue analyses revealed novel polypharmacology, including for MAPK, PI3K, and folate pathways inhibitors--as supported by Western blots, thermal shift assays, and structural analysis--as well as functional inhibitors of challenging oncoprotein targets, including MYC, CTNNB1, CENPF and UHRF1. The dataset and associated computational framework might be extensible to additional compound libraries, supporting global, quantitative approaches to defining the mechanisms of action of many drugs.

systems biology↗

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

The clinical use of potent androgen receptor (AR) inhibitors has promoted the emergence of novel subtypes of metastatic castration-resistant prostate cancer (mCRPC), including neuroendocrine prostate cancer (CRPC-NE), which is highly aggressive and lethal1. These mCRPC subtypes display increased lineage plasticity and often lack AR expression2-5. Here we show that neuroendocrine differentiation and castration-resistance in CRPC-NE are maintained by the activity of Nuclear Receptor Binding SET Domain Protein 2 (NSD2)6, which catalyzes histone H3 lysine 36 dimethylation (H3K36me2). We find that organoid lines established from genetically-engineered mice7 recapitulate key features of human CRPC-NE, and can display transdifferentiation to neuroendocrine states in culture. CRPC-NE organoids express elevated levels of NSD2 and H3K36me2 marks, but relatively low levels of H3K27me3, consistent with antagonism of EZH2 activity by H3K36me2. Human CRPC-NE but not primary NEPC tumors expresses high levels of NSD2, consistent with a key role for NSD2 in lineage plasticity, and high NSD2 expression in mCRPC correlates with poor survival outcomes. Notably, CRISPR/Cas9 targeting of NSD2 or expression of a dominant-negative oncohistone H3.3K36M mutant results in loss of neuroendocrine phenotypes and restores responsiveness to the AR inhibitor enzalutamide in mouse and human CRPC-NE organoids and grafts. Our findings indicate that NSD2 inhibition can reverse lineage plasticity and castration-resistance, and provide a potential new therapeutic target for CRPC-NE.

cancer biology↗